Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease
— Results From EMPA-REG OUTCOME® —

Kohei Kaku, MD; Jisoo Lee, MD; Michaela Mattheus; Stefan Kaspers, MD; Jyothis George, MD; Hans-Juergen Woerle, MD
on behalf of the EMPA-REG OUTCOME® Investigators

Background: In the EMPA-REG OUTCOME® trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular (CV) events (3-point MACE: composite of CV death, non-fatal myocardial infarction, or non-fatal stroke) by 14%, CV death by 38%, hospitalization for heart failure by 35%, and all-cause mortality by 32% in patients with type 2 diabetes (T2DM) and established CV disease. We investigated the effects of empagliflozin in patients of Asian race.

Methods and Results: Patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Of 7,020 patients treated, 1,517 (21.6%) were of Asian race. The reduction in 3-point MACE in Asian patients was consistent with the overall population: 3-point MACE occurred in 79/1,006 patients (7.9%) in the pooled empagliflozin group vs. 58/511 patients (11.4%) in the placebo group (hazard ratio: 0.68 [95% confidence interval: 0.48–0.95], P-value for treatment by race interaction (Asian, White, Black/African-American): 0.0872). The effects of empagliflozin on the components of MACE, all-cause mortality, and heart failure outcomes in Asian patients were consistent with the overall population (P-values for interaction by race >0.05). The adverse event profile of empagliflozin in Asian patients was similar to the overall trial population.

Conclusions: Reductions in the risk of CV outcomes and mortality with empagliflozin in Asian patients with T2DM and established CV disease were consistent with the overall trial population.

Key Words: Diabetes mellitus; Mortality; Race; Sodium-glucose cotransporter 2; Treatment outcomes

Editorial p ???

Advance Publication by-J-STAGE
Patients in the trial had T2DM (with HbA1c 7.0–9.0% for drug-naive patients and 7.0–10.0% for those on stable glucose-lowering therapy), established CV disease, and estimated glomerular filtration rate (eGFR; according to the Modification of Diet in Renal Disease [MDRD] equation) ≥20mL/min/1.73m². Patients were asked to select their race based on the following options: White, Asian, Black/African-American, American Indian or Native Alaskan, or Native Hawaiian or other Pacific Islander. Participants were randomized to receive empagliflozin 10mg, empagliflozin 25mg, or placebo once daily in addition to standard of care. Throughout the trial (or after week 12 for glucose-lowering medications), investigators were encouraged to treat CV risk factors to achieve optimal standard of care according to local guidelines. The trial was to continue until ≥691 patients experienced an adjudicated event included in the primary outcome (3-point MACE). Patients who prematurely discontinued study medication continued to be followed for ascertainment of CV outcomes and vital status.

The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines and was approved by local authorities. An independent ethics committee or institutional review board approved the clinical protocol at every participating center. All patients provided written informed consent before study entry.

**Outcomes**

Definitions of the major clinical outcomes in EMPA-REG OUTCOME® have been published. CV outcome events and deaths were prospectively adjudicated by Clinical Events committees (for cardiac and neurological events). Adverse events (AEs) were reported by investigators based on preferred terms in the Medical Dictionary for Regulatory Activities (MedDRA).

We analyzed the following CV/mortality outcomes in the subgroup of patients of Asian race: 3-point MACE, 4-point MACE (composite of CV death, non-fatal MI, non-fatal
stroke, or hospitalization for unstable angina), CV death, all-cause mortality, fatal or non-fatal stroke, non-fatal stroke, fatal or non-fatal MI, non-fatal MI, hospitalization for HF, composite of HF hospitalization or CV death. Subgroup analyses were conducted to investigate the consistency between the treatment effects on these outcomes observed in the Asian subgroup and the treatment effects in the other races (White, Black/African-American, other).

In addition, we analyzed changes in HbA1c, weight, systolic and diastolic blood pressure, heart rate, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, uric acid, and eGFR (according to the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation). AEs reported during treatment or within 7 days of the last intake of study drug and further clinical laboratory measurements were analyzed descriptively. CV outcomes were also assessed in patients from the East Asian region (Hong Kong, Japan, Korea, Taiwan), all of whom were of Asian race.

**Statistical Analysis**

Analyses were conducted following a modified intent-to-treat approach in patients treated with ≥1 dose of study drug (treated set). Treatment group differences across subgroups of race in the risk of CV outcomes and all-cause mortality were assessed using Cox proportional hazards models with treatment, age, sex, baseline body mass index (BMI), baseline HbA1c, baseline eGFR, region, race, and treatment by race interaction as factors. Cumulative incidence function estimates of 3-point MACE and CV death were corrected for death as a competing risk. Kaplan-Meier estimates are presented for all-cause mortality. Because of the declining numbers of patients at risk, cumulative incidence and Kaplan-Meier plots have been truncated at 48 months.

Changes from baseline in HbA1c, weight, systolic and diastolic blood pressure, heart rate, LDL- and HDL-cholesterol, uric acid and eGFR were assessed using mixed model repeated measures analysis with baseline HbA1c and the baseline value for the endpoint in question as linear covariates, and baseline BMI, baseline eGFR (MDRD), region, the last week a patient could have had a measurement for the endpoint in question, treatment, visit, visit by treatment interaction, visit by race interaction, treatment by visit by race interaction, visit by baseline HbA1c interaction, and visit by baseline value for the endpoint in question as fixed effects. All data from baseline to study end were considered for these analyses.

---

### Table: Glucose-lowering Therapies

|                      | Placebo (n=511) | Empagliflozin 10mg (n=505) | Empagliflozin 25mg (n=501) |
|----------------------|-----------------|-----------------------------|-----------------------------|
| **Cardiac failure**  | 25 (4.9)        | 24 (4.8)                    | 28 (5.6)                    |
| **Groups of race in the risk of CV outcomes and all-cause mortality** |                 |                             |                             |

Data are n (%) or mean ± SD in patients treated with ≥1 dose of study drug. *Participating countries from Asia: Hong Kong, India, Indonesia, Japan, Korea, Malaysia, Philippines, Singapore, Sri Lanka, Taiwan, Thailand. †Placebo, n=511; empagliflozin 10mg, n=504; empagliflozin 25mg, n=501. ‡Placebo, n=508; empagliflozin 10mg, n=502; empagliflozin 25mg, n=500. §Placebo, n=509; empagliflozin 10mg, n=502; empagliflozin 25mg, n=495. ¶Defined as any of the components of history of myocardial infarction, coronary artery bypass graft, multivessel CAD, single-vessel CAD. ‖Based on narrow standardized MedDRA query ‘cardiac failure’. ACE, angiotensin-converting enzyme; ARBs, angiotensin-receptor blockers; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDRD, Modification of Diet in Renal Disease; T2DM, type 2 diabetes mellitus.
Baseline Characteristics

A total of 1,517 of 7,020 patients (21.6%) identified themselves as of Asian race. The baseline characteristics of Asian patients were generally balanced between the placebo and empagliflozin groups (Table 1). Mean (SD) age was 61.0 (9.2) years, 73.7% were male, mean (SD) BMI was 26.6 (4.0) kg/m², mean (SD) HbA1c was 8.07 (0.85) %, mean (SD) eGFR was 73.9 (21.7) mL/min/1.73 m², 55.4% had multivessel coronary artery disease, 40.9% had a history of MI, 24.9% had a history of stroke, 17.7% had a coronary artery bypass graft, and 5.1% had cardiac failure. At baseline, 71.9% of Asian patients were on angiotensin-converting enzyme inhibitors and/or angiotensin-receptor blockers, 58.8% were on β-blockers, and 26.6% were on diuretics.

CV Outcomes

In the overall patient population, there was a significantly lower risk of 3-point MACE (primary outcome) in the empagliflozin group (490/4,687 patients [10.5%]) than in the placebo group (282/2,333 patients [12.1%]) (hazard ratio: 0.86 [95.02% CI: 0.74–0.99]). The reduction in 3-point MACE in Asian patients was consistent with the overall patient population: 3-point MACE occurred in 79/1,006 patients (7.9%) in the empagliflozin group vs. 58/511 patients (11.3%) in the placebo group.

Figure 1. CV outcomes in overall trial population and in Asian patients. P-value is for homogeneity of the treatment group difference among subgroups by race (Asian, White, Black/African-American, or Other), with no adjustment for multiple tests. CI, confidence interval; CV, cardiovascular; MACE, major adverse CV events.
Empagliflozin and CV Outcomes in Asian Patients

In Asian patients, the hazard ratio for CV death was 0.44 (95% CI: 0.25–0.78) and the hazard ratio for all-cause mortality was 0.64 (95% CI: 0.40–1.01), consistent with the hazard ratios in the overall patient population (CV death: 0.62 [95% CI: 0.49–0.77]; all-cause mortality: 0.68 [95% CI: 0.57–0.82]) (Figures 1A). In Asian patients, there was no difference between empagliflozin and placebo in the risk of stroke (hazard ratio: 0.95 [95% CI: 0.55–1.64]) or MI (hazard ratio: 0.62 [95% CI: 0.36–1.08]), consistent with the overall patient population (hazard ratio for stroke: 1.18 [95% CI: 0.89–1.56]; hazard ratio for MI: 0.87 [95% CI: 0.70–1.09]) (Figure 1). There were reductions in the risks of hospitalization for HF and the composite of HF hospitalization or CV death in Asian patients (hazard ratio for hospitalization for HF: 0.70 [95% CI: 0.37–1.33]; hazard ratio for the composite of HF hospitalization or CV death: 0.57 [95% CI: 0.36–0.89]), which were consistent with the overall patient population (hazard ratio for hospitalization for HF: 0.65 [95% CI: 0.50–0.85]; hazard ratio for the composite of HF hospitalization or CV death: 0.66 [95% CI: 0.55–0.79]) (Figure 1).

In patients from East Asian countries (pooled empagliflozin, n=397; placebo, n=189), the effects of empagliflozin on CV outcomes were comparable with the Asian subgroup, as well as the overall trial population (Table S1).

Glycemic Control
In Asian patients, at week 12, the adjusted mean differences in HbA1c between patients receiving empagliflozin (n=988) and placebo (n=503) were −0.48% (95% CI: −0.57 to −0.40) for empagliflozin 10 mg and −0.64% (95% CI: −0.73 to −0.55) for empagliflozin 25 mg (Figure 3). At week 94, the adjusted mean differences in HbA1c between Asian patients receiving empagliflozin (n=922) and placebo (n=463) were −0.44% (95% CI: −0.57 to −0.30) for empagliflozin 10 mg and −0.53% (95% CI: −0.66 to −0.40) for empagliflozin 25 mg. At week 206, the adjusted mean differences in HbA1c between Asian patients receiving empagliflozin (n=100) and placebo (n=40) were −0.15% (95% CI: −0.46 to 0.15) for empagliflozin 10 mg and −0.49% (95% CI: −0.80 to −0.19) for empagliflozin 25 mg. In Asian patients, the effects of empagliflozin on glycemic control were comparable with the overall trial population.

CV Risk Factors and Medications
Consistent with the overall trial population, in Asian patients, small reductions in weight, systolic blood pressure, diastolic blood pressure and uric acid, and small increases in LDL- and HDL-cholesterol, were observed with empagliflozin vs. placebo (Figure S1). There was no increase in heart rate.

Consistent with the overall results, a higher percentage of Asian patients in the placebo group received additional

![Figure 2](image1.png)

**Figure 2.** (A) Cumulative incidence of 3-point MACE (CV death, non-fatal myocardial infarction, or non-fatal stroke), (B) cumulative incidence of CV death, and (C) Kaplan-Meier estimate for all-cause mortality in Asian patients. Hazard ratios are based on Cox regression analyses in patients treated with ≥1 dose of study drug. HR, hazard ratio; other abbreviations as in Figure 1.

![Figure 3](image2.png)

**Figure 3.** Change from baseline in HbA1c in Asian patients. Mixed model repeated measures analysis in patients treated with ≥1 dose of study drug from baseline to study end.
glucose-lowering medications (most commonly a dipeptidyl peptidase-4 inhibitor or insulin) and antihypertensive medications (including diuretics) during the trial, with no differences in the introduction of anticoagulants or lipid-lowering drugs post-baseline (Tables S2,S3).

Safety and Tolerability

The AE profile of empagliflozin in Asian patients was consistent with that observed in the overall trial population. The percentages of Asian patients who had any AEs, serious AEs, or AEs leading to discontinuation of study drug were similar in the empagliflozin and placebo groups (Table 2). The proportions of patients with events consistent with genital infection (3.8%, 2.8% and 1.0% in the empagliflozin 10 mg, empagliflozin 25 mg and placebo groups, respectively) and volume depletion (4.0%, 5.4% and 3.3% in the empagliflozin 10 mg, empagliflozin 25 mg and placebo groups, respectively) were higher in patients treated with empagliflozin than placebo. Cancer was reported more frequently in patients treated with empagliflozin than placebo (1.6%, 3.2% and 1.6% in the empagliflozin 10 mg, empagliflozin 25 mg and placebo groups, respectively). The proportions of patients with events consistent with urinary tract infection, confirmed hypoglycemic AEs, acute renal failure, thromboembolic events, and bone fractures were similar in the empagliflozin and placebo groups. Diabetic ketoacidosis was reported in 1 patient treated with placebo and in none treated with empagliflozin.

Clinical laboratory parameters in Asian patients are shown in Table S4. No relevant changes in electrolytes were observed in any group. Hematocrit increased in patients treated with empagliflozin (mean ± SD changes from baseline: 5.2±5.5% in the empagliflozin 10 mg group, 5.0±5.4% in the empagliflozin 25 mg group, 1.1±5.0% in the placebo group). In the empagliflozin group, there was an initial decrease in eGFR followed by an increase to near baseline levels (Figure S1).

### Table 2. Adverse Events in Asian Patients

| Event                                | Placebo (n=511) | Empagliflozin 10 mg (n=505) | Empagliflozin 25 mg (n=501) |
|--------------------------------------|-----------------|-----------------------------|-----------------------------|
| Adverse event                        |                 |                             |                             |
| Serious adverse event                | 213 (41.7)      | 175 (34.7)                  | 184 (36.7)                  |
| Death                                | 23 (4.5)        | 12 (2.4)                    | 17 (3.4)                    |
| Drug-related* adverse event          | 136 (26.6)      | 137 (27.1)                  | 143 (28.5)                  |
| Adverse event leading to discontinuation | 81 (15.9)      | 67 (13.3)                  | 67 (13.4)                  |
| Event consistent with urinary tract infection† | 95 (18.6)      | 93 (18.4)                  | 85 (17.0)                  |
| Event consistent with genital infection‡ | 5 (1.0)        | 19 (3.8)                    | 14 (2.8)                    |
| Confirmed hypoglycemic adverse event‡ | 136 (26.6)      | 134 (26.5)                  | 121 (24.2)                  |
| Acute renal failure†                 | 29 (5.7)        | 29 (5.7)                    | 29 (5.8)                    |
| Event consistent with volume depletion‡ | 17 (3.3)        | 20 (4.0)                    | 27 (5.4)                    |
| Bone fracture‡                        | 16 (3.1)        | 23 (4.6)                    | 12 (2.4)                    |
| Thromboembolic event¶                | 5 (1.0)         | 2 (0.4)                     | 2 (0.4)                     |
| Cancer                               | 8 (1.6)         | 8 (1.6)                     | 16 (3.2)                    |
| Diabetic ketoacidosis††               | 1 (0.2)         | 0                           | 0                           |

Data are n (%) of patients treated with ≥1 dose of study drug who reported ≥1 of the respective type of adverse event during treatment or within 7 days of the last intake of study drug, except for data on cancer, which are all events reported up to termination of the trial. * As reported by the investigator. †Based on 79 preferred MedDRA terms. ‡Based on 88 MedDRA preferred terms. †Plasma glucose level <70 mg/dL (3.9 mmol/L) and/or requiring assistance. †Based on 1 standardized MedDRA query. †Based on 8 MedDRA preferred terms. **Based on 62 MedDRA preferred terms. ††Based on 4 MedDRA preferred terms. MedDRA, Medical Dictionary for Regulatory Activities.

Discussion

In the EMPA-REG OUTCOME® trial in patients with T2DM and established CV disease, empagliflozin given in addition to standard of care significantly reduced the risk of the primary outcome of 3-point MACE by 14%, driven by a 38% reduction in CV death.5 Our new analyses demonstrate that the reductions in risk of CV and mortality outcomes were consistent between Asian patients and the overall trial population. An additional analysis showed that the reductions in risk of CV/mortality outcomes were consistent between patients from East Asian countries and the overall trial population; however, it should be noted that a statistical test for consistency was not performed, and the number of East Asian patients with CV events was small. As observed in the overall trial population, reductions in the risks of CV death and all-cause mortality in Asian patients occurred early and were maintained throughout the trial.

Compared with the overall trial population, Asian patients had lower mean weight and BMI; smaller proportions had peripheral artery disease, coronary artery bypass graft, or a history of MI; and greater proportions had multivessel coronary artery disease. However, baseline characteristics were balanced between treatment groups. It should be noted that the benefits of empagliflozin observed in EMPA-REG OUTCOME® occurred in patients with T2DM and established CV disease receiving multiple medicines with proven CV benefits, such as renin-angiotensin-aldosterone system inhibitors, statins, β-blockers, and acetylsalicylic acid. Similar proportions of patients were taking antihypertensive medications at baseline in the Asian subgroup compared with the overall trial population; use of diuretics and angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers was lower in the Asian subgroup, but comparable between the empagliflozin and placebo groups.

Throughout the trial (and after week 12 for glucose-
Empagliflozin and CV Outcomes in Asian Patients

lowering medications), investigators were encouraged to treat CV risk factors to achieve optimal standard of care according to local guidelines. Consistent with the overall trial population, a small reduction in HbA1c was observed in Asian patients treated with empagliflozin vs. placebo. Empagliflozin was also associated with weight loss: the effects of empagliflozin on weight in Asian patients in EMPA-REG OUTCOME® were similar to those observed in the overall trial population and in Asian patients who participated in previous phase III trials.8 Reductions in weight with empagliflozin are mainly associated with reductions in visceral adiposity.4,9,10 This may be particularly important in Asian patients, who have more visceral adiposity than Caucasians at any given BMI.11 As observed in the overall trial population, empagliflozin reduced blood pressure in Asian patients, with no increase in heart rate.

The AE profile of empagliflozin in Asian patients was consistent with that reported in the overall trial population.6 Events consistent with genital infection were more common in Asian patients treated with empagliflozin than with placebo. There was a slight imbalance in the proportion of Asian patients with events consistent with volume depletion between the placebo and empagliflozin groups, but the percentage of Asian patients with such events was low in all treatment groups, consistent with the overall population. Other AEs of special interest were reported in similar proportions of Asian patients treated with empagliflozin and placebo. There were no cases of diabetic ketoacidosis in Asian patients treated with empagliflozin.

In the Asian subgroup, cancer events were reported in 8 (1.6%) patients, 16 (3.2%) patients and 8 (1.6%) patients in the empagliflozin 10 mg, empagliflozin 25 mg and placebo groups, respectively. In the overall trial population, no imbalance was observed between empagliflozin and placebo in the overall number of cancer events or in any specific subtype of cancer (data on file).

In EMPA-REG OUTCOME®, the reductions in risk of CV/mortality outcomes with empagliflozin occurred early, suggesting that the benefits were not primarily driven by an effect on atherosclerosis. The mechanisms behind the CV benefits of empagliflozin are believed to be multifactorial and may involve its effects on hyperglycemia, weight, visceral adiposity, uric acid, blood pressure, or arterial stiffness.5,8,12,13 Recently, it was suggested that the CV benefits observed with empagliflozin in EMPA-REG OUTCOME® may be driven by hemodynamic and renal effects that are particularly beneficial in patients with cardiac dysfunction.13 Empagliflozin has been shown to increase urinary glucose excretion and urine volume,14,15 leading to a reduction in fluid volume that may reduce cardiac pre- and afterload. Further, the transient increase in sodium excretion that occurs with empagliflozin activates tubuloglomerular feedback mechanisms that result in a decrease in glomerular pressure,16 addressing the maladaptive arteriolar responses seen in patients with T2DM.

These data support a reduction in CV outcomes and all-cause mortality in Asian patients with T2DM and established CV disease treated with empagliflozin in addition to standard of care. Limitations of these analyses include that patients who identified themselves as Asian based on the list of options provided for race were heterogeneous with respect to genetic, environmental, and cultural factors relevant to CV risk, and that the number of events in patients from East Asian countries was small.

Conclusion

Reductions in the risk of CV outcomes and all-cause mortality with empagliflozin vs. placebo were consistent between Asian patients and the overall patient population with T2DM and established CV disease in EMPA-REG OUTCOME®.

Acknowledgments

The authors thank the patients who participated in this trial. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Melanie Stephens and Wendy Morris of Fleshman Hillard Fishburn, London, UK during the preparation of this article. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development and have approved the final version.

Conflict of Interest Disclosures

K.K. reports receipt of lecture fees from Astellas Pharma, Novo Nordisk, Sanwa Kagaku Kenkyusho, Takeda, Taisho Pharmaceuticals, Merck Sharp and Dohme, Kowa Pharmaceuticals, Kissel Pharmaceuticals, Sumitomo Dainippon Pharma, Novartis, Mitsubishi Tanabe Pharma, AstraZeneca, Nippon Boehringer Ingelheim, Daiichi Sankyo, FujiFilm Pharma and Sanofi, and research support from Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Daiichi Sankyo and Taisho Pharmaceuticals. J.H., M.M., S.K., J.G., and H.-J.W. are all employees of Boehringer Ingelheim.

Funding

The EMPA-REG OUTCOME® trial was funded by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance.

References

1. International Diabetes Federation, IDF Atlas (7th edn) 2015. http://www.diabetesatlas.org/ (accessed November 8, 2016).
2. Golden SH, Brown A, Cauley JA, Chin MH, Gary-Webb TL, Kim C, et al. Health disparities in endocrine disorders: Biological, clinical, and nonclinical factors: An Endocrine Society scientific statement. J Clin Endocrinol Metab 2012; 97: E1579–E1639.
3. Tillin T, Hughes AD, Mayet J, Whincup P, Sattar N, Forouhi NG, et al. The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited): A prospective population-based study. J Am Coll Cardiol 2013; 61: 1777–1786.
4. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010; 375: 408–418.
5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
6. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016; 37: 1526–1534.
7. Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME®). Cardiovasc Diabetol 2014; 13: 102.
8. Yoon KH, Nishimura R, Lee J, Crowe S, Salsali A, Hach T, et al. Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: Pooled data from four phase III trials. Diabetes Obes Metab 2016; 18: 1045–1049.
9. Riddorstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691–700.
10. Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2016; 18: 119–126.
11. Ma RC, Chan JC. Type 2 diabetes in East Asians: Similarities
and differences with populations in Europe and the United States. 
Ann NY Acad Sci 2013; 1281: 64–91.

12. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015; 17: 1180–1193.

13. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: Why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia 2016; 59: 1333–1339.

14. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes. Clin Ther 2016; 38: 2265–2276.

15. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus. Clin Ther 2016; 38: 2248–2264.

16. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587–597.

Supplementary Files

Supplementary File 1

Figure S1. Weight, systolic and diastolic blood pressure, heart rate, low density and high density lipoprotein-cholesterol, uric acid and eGFR over time in Asian patients.

Table S1. CV outcomes in patients from the East Asian Region

Table S2. Glucose-lowering medications introduced post-baseline in Asian patients

Table S3. CV medications introduced post-baseline in Asian patients

Table S4. Clinical laboratory parameters in Asian patients

Please find supplementary file(s);
http://dx.doi.org/10.1253/circj.CJ-16-1148